These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 33632095)

  • 21. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valinomycin as a potential antiviral agent against coronaviruses: A review.
    Zhang D; Ma Z; Chen H; Lu Y; Chen X
    Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives for repurposing drugs for the coronavirus disease 2019.
    Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
    Jácome R; Campillo-Balderas JA; Ponce de León S; Becerra A; Lazcano A
    Sci Rep; 2020 Jun; 10(1):9294. PubMed ID: 32518317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes.
    Lin MH; Moses DC; Hsieh CH; Cheng SC; Chen YH; Sun CY; Chou CY
    Antiviral Res; 2018 Feb; 150():155-163. PubMed ID: 29289665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
    Strayer DR; Dickey R; Carter WA
    Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
    Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.
    Dyall J; Coleman CM; Hart BJ; Venkataraman T; Holbrook MR; Kindrachuk J; Johnson RF; Olinger GG; Jahrling PB; Laidlaw M; Johansen LM; Lear-Rooney CM; Glass PJ; Hensley LE; Frieman MB
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4885-93. PubMed ID: 24841273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
    Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
    Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.
    Saleki K; Yaribash S; Banazadeh M; Hajihosseinlou E; Gouravani M; Saghazadeh A; Rezaei N
    Eur J Pharmacol; 2021 Sep; 906():174248. PubMed ID: 34126092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
    İnandıklıoğlu N; Akkoc T
    Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses.
    Ahn DG; Yoon GY; Lee S; Ku KB; Kim C; Kim KD; Kwon YC; Kim GW; Kim BT; Kim SJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452503
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.